Tocilizumab versus the Covid19 tempest: All’s well that ends well or much ado about nothing?
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- February 2021
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Antibodies, Monoclonal, Humanized (MeSH)
- COVID-19 Drug Treatment (MeSH)
- Humans (MeSH)
- Microbiology (Science Metrix)
- SARS-CoV-2 (MeSH)